MCID: CTN003
MIFTS: 55

Cutaneous Lupus Erythematosus

Categories: Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Cutaneous Lupus Erythematosus

MalaCards integrated aliases for Cutaneous Lupus Erythematosus:

Name: Cutaneous Lupus Erythematosus 12 77 54 38 15 17
Lupus Erythematosus, Cutaneous 54 74
Lupus Erythematosus Cutaneous 56

Classifications:



External Ids:

Disease Ontology 12 DOID:0050169
KEGG 38 H01595
UMLS 74 C0024137

Summaries for Cutaneous Lupus Erythematosus

Disease Ontology : 12 A lupus erythematosus that causes skin lesions on parts of the body that are exposed to sunlight.

MalaCards based summary : Cutaneous Lupus Erythematosus, also known as lupus erythematosus, cutaneous, is related to subacute cutaneous lupus erythematosus and vasculitis, and has symptoms including pruritus and exanthema. An important gene associated with Cutaneous Lupus Erythematosus is CXCR3 (C-X-C Motif Chemokine Receptor 3), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Hydroxychloroquine and Ustekinumab have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and heart, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 77 Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes... more...

Related Diseases for Cutaneous Lupus Erythematosus

Diseases in the Cutaneous Lupus Erythematosus family:

Subacute Cutaneous Lupus Erythematosus

Diseases related to Cutaneous Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 225)
# Related Disease Score Top Affiliating Genes
1 subacute cutaneous lupus erythematosus 34.1 CD70 EEA1 TNF TRIM21
2 vasculitis 30.3 ICAM1 SELE TNF
3 chilblain lupus 1 30.1 MX1 TREX1 TRIM21
4 keratoconjunctivitis 29.8 ICAM1 IFNG TNF
5 actinic prurigo 29.8 ICAM1 SELE TNF
6 rheumatoid arthritis 29.7 ICAM1 IFNG IL18 SELE TNF
7 skin disease 29.7 ICAM1 IFNG SELE TNF
8 sialadenitis 29.5 TNF TRIM21
9 lymphadenitis 29.5 CXCR3 ICAM1 IFNG IL18 TNF
10 bronchiolitis obliterans 29.3 CXCR3 GZMB IFNG TNF
11 alopecia areata 29.1 GZMB ICAM1 IFNG TNF
12 erythema multiforme 29.1 CXCR3 GZMB ICAM1 IFNG TNF
13 lichen planus 29.0 CXCR3 GZMB ICAM1 IFNG MX1 TNF
14 systemic lupus erythematosus 28.4 CD70 CXCR3 ICAM1 IFNG IL18 MX1
15 lupus erythematosus tumidus 11.9
16 neonatal lupus erythematosus 11.6
17 lupus erythematosus 11.3
18 dermatomyositis 10.4
19 encephalitozoonosis 10.4 MX1 TNF
20 systemic onset juvenile idiopathic arthritis 10.4 IL18 TNF
21 cat-scratch disease 10.3 EEA1 IFNG
22 staphylococcal toxic shock syndrome 10.3 IFNG TNF
23 autoimmune myocarditis 10.3 IFNG TNF
24 trichosporonosis 10.3 IFNG TNF
25 chronic beryllium disease 10.3 IFNG TNF
26 listeria meningitis 10.3 IL18 TNF
27 miliary tuberculosis 10.3 IFNG TNF
28 chronic graft versus host disease 10.3 IFNG TNF
29 melanoma metastasis 10.3 IL18 TNF
30 clonorchiasis 10.3 IFNG TNF
31 microscopic colitis 10.3 IFNG TNF
32 crohn's colitis 10.3 IFNG TNF
33 stachybotrys chartarum 10.3 IL18 TNF
34 discoid lupus erythematosus 10.3
35 critical limb ischemia 10.3 SELE TNF
36 meconium aspiration syndrome 10.3 IFNG TNF
37 central nervous system vasculitis 10.3 IFNG TNF
38 retinitis pigmentosa 60 10.2 SELE TNF
39 african tick-bite fever 10.2 IFNG SELE
40 diffuse infiltrative lymphocytosis syndrome 10.2 TNF TRIM21
41 shwartzman phenomenon 10.2 ICAM1 TNF
42 soft tissue sarcoma 10.2 IFNG TNF
43 severe acute respiratory syndrome 10.2 IFNG MX1 TNF
44 alopecia 10.2
45 arthritis 10.2
46 psoriasis 10.2
47 mycoplasma pneumoniae pneumonia 10.2 IFNG IL18 TNF
48 pleural tuberculosis 10.2 IFNG IL18 TNF
49 mouth disease 10.2 IFNG MX1 TNF
50 inflammatory bowel disease 3 10.2 IL18 TNF

Graphical network of the top 20 diseases related to Cutaneous Lupus Erythematosus:



Diseases related to Cutaneous Lupus Erythematosus

Symptoms & Phenotypes for Cutaneous Lupus Erythematosus

UMLS symptoms related to Cutaneous Lupus Erythematosus:


pruritus, exanthema

GenomeRNAi Phenotypes related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 CD70 GZMB ICAM1 IL18 MX1 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 CD70 GZMB ICAM1 IL18 MX1 TNF

MGI Mouse Phenotypes related to Cutaneous Lupus Erythematosus:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 CD70 CXCR3 ICAM1 IFNG IL18 SELE
2 homeostasis/metabolism MP:0005376 9.91 CXCR3 ICAM1 IFNG IL18 KRT15 SELE
3 digestive/alimentary MP:0005381 9.85 ICAM1 IFNG IL18 KRT15 TNF TREX1
4 immune system MP:0005387 9.81 CD70 CXCR3 ICAM1 IFNG IL18 SELE
5 integument MP:0010771 9.5 ICAM1 IFNG IL18 SELE TNF TREX1
6 vision/eye MP:0005391 9.1 ICAM1 IFNG IL18 SELE TNF TREX1

Drugs & Therapeutics for Cutaneous Lupus Erythematosus

Drugs for Cutaneous Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxychloroquine Approved Phase 3,Phase 2 118-42-3 3652
2
Ustekinumab Approved, Investigational Phase 3 815610-63-0
3
tannic acid Approved Phase 3,Phase 2 1401-55-4
4
Benzocaine Approved, Investigational Phase 3,Phase 2 94-09-7, 1994-09-7 2337
5 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
6 Anti-Infective Agents Phase 3,Phase 2
7 Antimalarials Phase 3,Phase 2
8 Antiparasitic Agents Phase 3,Phase 2
9 Antiprotozoal Agents Phase 3,Phase 2
10 Protective Agents Phase 3,Not Applicable
11 Dermatologic Agents Phase 3,Phase 2,Not Applicable
12 Radiation-Protective Agents Phase 3,Not Applicable
13 Sunscreening Agents Phase 3,Not Applicable
14
Etanercept Approved, Investigational Phase 2 185243-69-0
15
Norflurane Approved, Experimental Phase 2 811-97-2
16
Tacrolimus Approved, Investigational Phase 2,Not Applicable 104987-11-3 445643 439492 6473866
17
Dimethyl fumarate Approved, Investigational Phase 2 624-49-7 637568 5271565
18
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
19
Alitretinoin Approved, Investigational Phase 2 5300-03-8 444795 449171
20
Apremilast Approved, Investigational Phase 1, Phase 2 608141-41-9 11561674
21
Tofacitinib Approved, Investigational Phase 1, Phase 2,Early Phase 1 477600-75-2
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
23
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
24
Calcium Approved, Nutraceutical Phase 2,Early Phase 1 7440-70-2 271
25
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
26
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 5280795 6221
27
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
28 Sifalimumab Investigational Phase 2 162635-04-3, 1006877-41-3 23724530
29 Antibodies Phase 1, Phase 2,Phase 2,Early Phase 1
30 Immunoglobulins Phase 1, Phase 2,Phase 2,Early Phase 1
31 Antibodies, Monoclonal Phase 1, Phase 2,Phase 2
32 Anti-Inflammatory Agents, Non-Steroidal Phase 2,Phase 1,Not Applicable
33 Immunosuppressive Agents Phase 2,Not Applicable
34 Peripheral Nervous System Agents Phase 2,Phase 1,Not Applicable
35 Anti-Inflammatory Agents Phase 2,Phase 1,Not Applicable
36 Immunologic Factors Phase 2,Early Phase 1,Not Applicable
37 Analgesics Phase 2,Phase 1,Not Applicable
38 Analgesics, Non-Narcotic Phase 2,Phase 1,Not Applicable
39 Gastrointestinal Agents Phase 2
40 Calcineurin Inhibitors Phase 2,Not Applicable
41 Vitamin B3 Phase 2
42 Micronutrients Phase 2
43 Folate Phase 2
44 Lipid Regulating Agents Phase 2
45 Vitamin B9 Phase 2
46 Vasodilator Agents Phase 2
47 Vitamins Phase 2
48 Hypolipidemic Agents Phase 2
49 Nicotinic Acids Phase 2
50 Trace Elements Phase 2

Interventional clinical trials:

(show top 50) (show all 70)
# Name Status NCT ID Phase Drugs
1 Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion Completed NCT01551069 Phase 3 hydroxychloroquine (Z0188);Placebo
2 Sunscreen RV 2457C in Photoinduced CLE Completed NCT00470912 Phase 3 sunscreen RV 2547C
3 Efficacy of 595 nm Pulsed-dye Laser in Treatment of Discoid Lupus Erythematosus Recruiting NCT03178188 Phase 2, Phase 3
4 A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus Recruiting NCT03517722 Phase 3 Placebo;Ustekinumab (approximately 6 mg/kg);Ustekinumab 90 mg
5 A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) Not yet recruiting NCT03843125 Phase 3 Baricitinib
6 A Study of Baricitinib in Participants With Systemic Lupus Erythematosus Recruiting NCT03616964 Phase 3 Baricitinib;Placebo
7 A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus Recruiting NCT03616912 Phase 3 Baricitinib;Placebo
8 Phase Ib Study of SC Milatuzumab in SLE Unknown status NCT01845740 Phase 1, Phase 2 milatuzumab;Placebo
9 The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus Unknown status NCT00797784 Phase 2 etanercept(Enbrel®)
10 Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) Recruiting NCT02847598 Phase 2 BIIB059;Placebo
11 Safety and Efficacy of Filgotinib and GS-9876 in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) Active, not recruiting NCT03134222 Phase 2 Filgotinib;GS-9876;Filgotinib placebo;GS-9876 placebo
12 Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser Completed NCT00523588 Phase 2
13 Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus Completed NCT01294774 Phase 2 KRP203 - 1.2mg;Placebo to KRP203 - 1.2 mg
14 To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus Completed NCT01300208 Phase 2 CC-11050
15 Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE) Completed NCT00317681 Phase 2 Tacrolimus ointment
16 Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus Completed NCT01352988 Phase 2 Fumaric acid esters
17 Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus Recruiting NCT03260166 Phase 2 nicotinamide
18 Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus Terminated NCT01407679 Phase 2 Alitretinoin
19 Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus Terminated NCT01498406 Phase 2
20 Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients Completed NCT00708916 Phase 1, Phase 2 CC-10004
21 A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE) Recruiting NCT02660944 Phase 2 RSLV-132;Placebo
22 Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus Recruiting NCT03288324 Phase 1, Phase 2 Tofacitinib
23 Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus Completed NCT02656082 Phase 2 Etanercept
24 A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus Not yet recruiting NCT03866317 Phase 2 Secukinumab
25 TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment Terminated NCT02711813 Phase 2 TAB08
26 Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus Completed NCT02265744 Phase 2 BMS-931699;Placebo matching BMS-931699
27 A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus Terminated NCT01466725 Phase 2 CC-930;Placebo
28 A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus Completed NCT01283139 Phase 2
29 A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus Completed NCT02437890 Phase 2
30 Safety and Efficacy of AMG 592 in Subjects With Active Systemic Lupus Erythematosus Recruiting NCT03451422 Phase 1, Phase 2 AMG 592;Placebo
31 An Investigational Study to Evaluate BMS-986165 in Patients With Systemic Lupus Erythematosus Recruiting NCT03252587 Phase 2 BMS-986165
32 A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Not yet recruiting NCT03845517 Phase 2 Placebo;PF-06700841 15 mg;PF-06700841 30 mg;PF-06700841 45 mg
33 A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE) Recruiting NCT02975336 Phase 2 Placebo;M2951;M2951;M2951;M2951
34 Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care Recruiting NCT03371251 Phase 1, Phase 2 BOS161721;Placebo
35 Study of Anti-Malarials in Incomplete Lupus Erythematosus Recruiting NCT03030118 Phase 2 Hydroxychloroquine;Placebo Oral Capsule
36 Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions Completed NCT01597050 Phase 2 R932333;Placebo
37 Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions Completed NCT00625521 Phase 2 ASF 1096 0.5 % cream applied twice daily;Cream vehicle for ASF 1096 cream applied twice daily
38 Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (2) Completed NCT00625157 Phase 2 ASF 1096 0.5 % cream;ASF 1096 placebo cream
39 Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva Terminated NCT00308204 Phase 2 Raptiva (efalizumab)
40 A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus Completed NCT00001680 Phase 2 Thalidomide
41 Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children Completed NCT00502593 Phase 2
42 A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus Terminated NCT01470313 Phase 1 PD-0360324;Placebo
43 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects Completed NCT02927457 Phase 1 GSK2646264 1%;Placebo
44 A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus Completed NCT01702740 Phase 1 1 mg/kg CNTO 136;4 mg/kg CNTO 136;10 mg/kg CNTO 136;Placebo
45 A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis Recruiting NCT03817424 Phase 1 VIB7734;Placebo
46 Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus Terminated NCT01389895 Phase 1 AMG 557;AMG 557 Placebo
47 Autologous Polyclonal Tregs for Lupus Active, not recruiting NCT02428309 Phase 1
48 Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus Terminated NCT01164917 Phase 1 AMG811;AMG811 Placebo
49 A Study of NKTR-358 in Participants With Systemic Lupus Erythematosis (SLE) Recruiting NCT03556007 Phase 1 NKTR-358;Placebo
50 Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus Completed NCT01629784 Not Applicable

Search NIH Clinical Center for Cutaneous Lupus Erythematosus

Genetic Tests for Cutaneous Lupus Erythematosus

Anatomical Context for Cutaneous Lupus Erythematosus

MalaCards organs/tissues related to Cutaneous Lupus Erythematosus:

42
Skin, Lung, Heart, Kidney, T Cells, Bone, Breast

Publications for Cutaneous Lupus Erythematosus

Articles related to Cutaneous Lupus Erythematosus:

(show top 50) (show all 889)
# Title Authors Year
1
Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus. ( 30227141 )
2019
2
Canine Cutaneous Lupus Erythematosus: Newly Discovered Variants. ( 30227971 )
2019
3
Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations. ( 30243657 )
2019
4
Neonatal cutaneous lupus erythematosus. ( 30580253 )
2019
5
Applying the Cutaneous Lupus Erythematosus Disease Area and Severity Index to paediatric cutaneous lupus erythematosus. ( 30604554 )
2019
6
Dapsone: an old drug effective for subacute cutaneous lupus erythematosus. ( 30615176 )
2019
7
Validation and Reliability of a Disease-Specific Quality of Life Measure in Patients with Cutaneous Lupus Erythematosus: CLEQoL. ( 30637718 )
2019
8
Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients. ( 30719729 )
2019
9
Are there distinct clinical and pathological features distinguishing Idiopathic from Drug-Induced Subacute Cutaneous Lupus Erythematosus? A European retrospective multicenter study. ( 30763648 )
2019
10
Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFNα Production From Patients Affected With Cutaneous Lupus Erythematosus. ( 30846987 )
2019
11
Chronic Cutaneous Lupus Erythematosus: Depression Burden and Associated Factors. ( 30877492 )
2019
12
Inflammatory chemokine profiles and their correlations with effector CD4 T cell and regulatory cell subpopulations in cutaneous lupus erythematosus. ( 30903869 )
2019
13
Subacute cutaneous lupus erythematosus: is clopidogrel a trigger? ( 29327459 )
2018
14
CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study. ( 29728857 )
2018
15
Subacute Cutaneous Lupus Erythematosus Induced by Palbociclib. ( 29307217 )
2018
16
Cutaneous lupus erythematosus: clinico-pathologic correlation. ( 29368845 )
2018
17
Autoimmune Diseases in Patients With Cutaneous Lupus Erythematosus. ( 29801110 )
2018
18
Drug-induced Subacute Cutaneous Lupus Erythematosus Caused by a Topical Beta Blocker - Timolol. ( 29782299 )
2018
19
Cutaneous lupus erythematosus, morphea profunda and psoriasis: A case report. ( 29625815 )
2018
20
Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: A multicenter retrospective study. ( 29496481 )
2018
21
Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis. ( 28989111 )
2018
22
Subacute cutaneous lupus erythematosus presenting in twins. ( 29436018 )
2018
23
Natural History of Disease Activity and Damage in Patients with Cutaneous Lupus Erythematosus. ( 29969701 )
2018
24
Autoantibody profile and clinical patterns in 619 Italian patients with cutaneous lupus erythematosus. ( 29924416 )
2018
25
Incremental health care services and expenditures associated with depression among individuals with cutaneous lupus erythematosus (CLE). ( 29514557 )
2018
26
The devil's in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda. ( 29631513 )
2018
27
Occupational subacute cutaneous lupus erythematosus caused by outdoor work. ( 29603599 )
2018
28
Matrix metalloproteinase-2 and -9 activity levels increase in cutaneous lupus erythematosus lesions and correlate with disease severity. ( 29349515 )
2018
29
Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study. ( 29061479 )
2018
30
Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus. ( 29924233 )
2018
31
Cutaneous lupus erythematosus in dogs: a comprehensive review. ( 29669547 )
2018
32
Disease severity and prophylactic measures in patients with cutaneous lupus erythematosus: results of a worldwide questionnaire-based study. ( 29760621 )
2018
33
Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark. ( 29788808 )
2018
34
Increased risk of depression in patients with cutaneous lupus erythematosus and systemic lupus erythematosus: a Danish nationwide cohort study. ( 29885269 )
2018
35
Ten-year retrospective clinicohistological study of cutaneous lupus erythematosus in Korea. ( 29423919 )
2018
36
Chronic Cutaneous Lupus Erythematosus in a Blaschkoid Pattern over Face. ( 29692464 )
2018
37
Coexistence of chronic cutaneous lupus erythematosus and frontal fibrosing alopecia. ( 29723351 )
2018
38
Successful treatment of severe subacute cutaneous lupus erythematosus with rituximab in an adolescent. ( 29570834 )
2018
39
Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern United States: The Georgia Lupus Registry. ( 29669194 )
2018
40
Obliterative Bronchiolitis as a Systemic Manifestation of Cutaneous Lupus Erythematosus. ( 30601199 )
2018
41
The incidence of herpes zoster in cutaneous lupus erythematosus (CLE), dermatomyositis (DM), pemphigus vulgaris (PV), and bullous pemphigoid (BP). ( 30521827 )
2018
42
Reply to: S2k guideline for treatment of cutaneous lupus erythematosus-guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). ( 30098058 )
2018
43
Novel biological therapeutic approaches to cutaneous lupus erythematosus. ( 30118337 )
2018
44
Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients. ( 30133802 )
2018
45
Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus: report of a case and review of the literature. ( 30142736 )
2018
46
Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional Study. ( 30148164 )
2018
47
Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept. ( 30167444 )
2018
48
Understanding the disease burden and unmet needs among patients with cutaneous lupus erythematosus: A qualitative study. ( 30175217 )
2018
49
Usefulness of Pulsed Dye Laser in Cutaneous Lupus Erythematosus. ( 30213381 )
2018
50
Drug-Induced Cutaneous Lupus Erythematosus: A Case Series of Five Patients with Bupropion-Associated Disease. ( 30222626 )
2018

Variations for Cutaneous Lupus Erythematosus

Expression for Cutaneous Lupus Erythematosus

Search GEO for disease gene expression data for Cutaneous Lupus Erythematosus.

Pathways for Cutaneous Lupus Erythematosus

Pathways related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 CD70 EEA1 ICAM1 IFNG IL18 MX1
2
Show member pathways
13.11 CD70 ICAM1 IFNG IL18 MX1 TNF
3
Show member pathways
12.7 GZMB ICAM1 IFNG IL18 TNF
4
Show member pathways
12.62 IFNG IL18 TNF TREX1
5
Show member pathways
12.4 ICAM1 IFNG IL18 MX1 TNF
6
Show member pathways
12.38 ICAM1 IFNG MX1 TRIM21
7
Show member pathways
12.35 GZMB ICAM1 IFNG TNF
8
Show member pathways
12.12 IFNG IL18 MX1 TNF
9 12.03 EEA1 IFNG IL18 TNF
10
Show member pathways
11.93 IFNG IL18 TNF
11 11.88 ICAM1 IFNG TNF
12 11.88 ICAM1 IFNG SELE TNF
13 11.86 ICAM1 IL18 TNF
14
Show member pathways
11.85 GZMB IFNG IL18
15 11.83 ICAM1 SELE TNF
16 11.77 ICAM1 SELE TNF
17 11.66 ICAM1 IFNG SELE
18 11.58 ICAM1 IFNG IL18 TNF
19 11.57 IFNG IL18 TNF
20
Show member pathways
11.5 GZMB IFNG TNF
21 11.46 CXCR3 GZMB IFNG IL18 TNF
22 11.38 ICAM1 IL18 TNF
23
Show member pathways
11.36 ICAM1 IFNG SELE TNF
24 11.35 IFNG IL18 TNF
25 11.12 IFNG TNF
26 11.1 IFNG IL18
27 11.09 IFNG IL18 TNF
28 11.07 CD70 IL18 TNF
29 11.04 ICAM1 IFNG IL18 SELE TNF
30 10.99 IL18 TNF
31 10.94 IFNG IL18
32 10.94 ICAM1 IFNG IL18
33 10.84 ICAM1 TNF
34 10.59 ICAM1 IFNG IL18 SELE TNF

GO Terms for Cutaneous Lupus Erythematosus

Biological processes related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.87 CD70 IFNG IL18 TNF
2 inflammatory response GO:0006954 9.81 CXCR3 IL18 SELE TNF
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.72 ICAM1 IL18 TNF
4 immune response GO:0006955 9.72 CD70 CXCR3 IFNG IL18 TNF
5 response to virus GO:0009615 9.65 IFNG MX1 TNF
6 interferon-gamma-mediated signaling pathway GO:0060333 9.61 ICAM1 IFNG TRIM21
7 leukocyte cell-cell adhesion GO:0007159 9.59 ICAM1 SELE
8 negative regulation of myoblast differentiation GO:0045662 9.58 IL18 TNF
9 positive regulation of protein complex assembly GO:0031334 9.58 IFNG TNF
10 natural killer cell mediated cytotoxicity GO:0042267 9.56 GZMB IL18
11 positive regulation of osteoclast differentiation GO:0045672 9.54 IFNG TNF
12 leukocyte tethering or rolling GO:0050901 9.52 SELE TNF
13 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.49 IFNG TNF
14 regulation of type I interferon production GO:0032479 9.46 TREX1 TRIM21
15 extrinsic apoptotic signaling pathway GO:0097191 9.43 CD70 IFNG TNF
16 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.4 ICAM1 TNF
17 positive regulation of neuroinflammatory response GO:0150078 9.37 IL18 TNF
18 positive regulation of nitric oxide biosynthetic process GO:0045429 9.33 ICAM1 IFNG TNF
19 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 8.96 IFNG TNF
20 positive regulation of vitamin D biosynthetic process GO:0060557 8.62 IFNG TNF

Molecular functions related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 CD70 IFNG IL18 TNF

Sources for Cutaneous Lupus Erythematosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....